Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 214

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 214
---
 for our products, once approved, or additional pricing pressures.

Competition

We also face competition from numerous sources including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Many of our competitors may have significantly greater research capabilities, as well as financial, product development, manufacturing, and marketing resources.

There are no currently approved
products with an FAP indication although certain non-steroidal anti-inflammatory drugs may be prescribed off-label. Panbela Therapeutics,
Inc. and Recursion Pharmaceuticals, Inc. are developing products for FAP. Standard of care treatment for NMIBC usually involves transurethral resection of the tumor followed by intravesical Bacillus Calmette-Gu érin therapy. A number of companies are developing therapeutics for NMIBC including Janssen Pharmaceuticals, CG Oncology, Inc. and Protara Therapeutics, Inc.

| 105 |

There are relatively few products
available for the treatment of T1D. Exogenous insulin in its various forms is used to compensate for the lack of endogenous insulin common
to all T1D patients. More recently, teplizumab, the first disease-modifying treatment of T1D, has been approved for the delay of Stage
3 T1D. A number of companies are researching potentially disease-modifying approaches to T1D including stem cell therapies by Vertex Pharmaceuticals,
Inc. and CRISPR Therapeutics AG and SAB Biotherapeutics, Inc. is developing an immunotherapeutic. The JDRF T1D Fund has invested in approximately
30 private companies working on a variety of approaches to the treatment of T1D. There are over 400 studies listed as recruiting in T1D
based on the clinicaltrials.gov website.

There are a limited number
of products approved for the treatment of GBM with the current standard of care being surgical resection followed by radiation in combination
with temozolomide. There is no formalized standard of care for the treatment of recurrent GBM or DMG. There are a number of companies
researching potential therapeutic treatments of GBM including CNS Pharmaceuticals, Inc. and Plus Therapeutics, Inc. Chimerix Inc. is among
a number of companies developing a product for DMG. There are approximately 340 studies listed as recruiting in GBM and approximately
70 studies recruiting in DMG based on the clinicaltrials.gov website.

Manufacturing

We do not have our own manufacturing
facilities and we